

Thomas Jefferson University Jefferson Digital Commons

Phase 1 Class of 2022

1-2020

Protocol for Ground Glass Opacity

Elissa Goldman

Thomas Jefferson University, elissa.goldman@jefferson.edu

Follow this and additional works at: https://jdc.jefferson.edu/si_ctr_2022_phase1

Part of the Oncology Commons, Pulmonology Commons, and the Translational Medical Research Commons

Let us know how access to this document benefits you

Recommended Citation

Goldman, Elissa, "Protocol for Ground Glass Opacity" (2020). *Phase 1.* Paper 61. https://jdc.jefferson.edu/si_ctr_2022_phase1/61

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Phase 1 by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Abstract

Rationale: Pure ground glass opacities (GGO), identified incidentally or on lung cancer screening, may indicate pre-invasive subtypes of lung adenocarcinoma. These neoplasms typically demonstrate indolent patterns of growth, and Fleischner Society guidelines recommend up to five years of serial imaging. Our aim was to determine the frequency of diagnosed lung adenocarcinoma arising from GGO detected beyond 5 years of CT surveillance.

Methods: We reviewed all pathologic diagnoses of lung adenocarcinoma (n=442) between 2016 and 2018 of a tertiary academic hospital and National Cancer Institute-designated cancer center to identify all cancers that arose from ground glass opacities detected on CT scan. Data extracted from the EMR included demographics, imaging characteristics and clinical outcomes.

Results: Of the 442 cases of lung adenocarcinoma, 32 (7%) were found that arose from pure GGOs and were ultimately diagnosed as cancer. Among the subgroup of GGOs, 74% (n=24) were diagnosed within the first five years of surveillance, but up to 26% (n=8) required between five and twelve years of serial follow up prior to definitive diagnosis. In order to detect 95% of cancers, GGOs would need to be followed for 7.9 to 12.7 years based upon a Kaplan-Meier estimate for time to diagnosis (p =0 .05). No patients who had lung adenocarcinoma arising from GGOs died (0/31) within a follow-up time of one to three years.

Conclusion: These data suggest that a greater number of lung adenocarcinomas would be detected upon routine follow up of GGOs that extended beyond the current recommendation of five years. Furthermore, the overall survival of the cohort was 100% (with one to three years of follow-up) consistent with existing data that these cancers are indolent. It is unknown whether a

higher detection rate would impact overall survival. More extended observation time and a prospective approach are required for confirmation of our findings.